+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the AGENT Drug-Coated Balloon DCB compared to standard percutaneous coronary intervention PCI treatments like drug-eluting stents DES and balloon angioplasty in patients with new de novo coronary artery lesions. This open-label, randomized controlled study includes a pharmacokinetic sub-study and an intravascular ultrasound sub-study to provide additional insights. Participants will be randomly assigned to receive either the AGENT DCB or standard care, which may include drug-eluting stents or balloon angioplasty. The study covers different lesion types such as small vessel, bifurcation with side branches, and long lesions, with treatments tailored accordingly. The procedures are performed as part of PCI, and treatment allocation is done in parallel groups. During the trial, participants will undergo follow-up evaluations to monitor lesion outcomes and safety, including assessments up to 12 months after the procedure. Researchers will measure the rate of target lesion failure at 12 months as the primary outcome. Participants will also be monitored for adherence to protocol and any adverse events, with the overall study lasting until March 2032.

Age: 18Years +All GendersPhase Not Applicable
71 locations
P

Actively Recruiting

Researchers are evaluating the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people with heart failure who have reduced ejection fraction. This registry study includes subjects recently implanted with the device under approved criteria for heart failure, specifically those with New York Heart Association NYHA functional Class III and left ventricular ejection fraction LVEF of 35% or less despite guideline-directed therapy. The study aims to understand how this therapy performs in a real-world commercial setting. Participants who received the BAROSTIM NEO System within 30 days before enrollment will be followed. Data will be collected from standard care measurements taken before implantation, at enrollment, and then at 3, 6, and 12 months after implantation. The study will track changes in heart failure severity, exercise capacity, heart function, biomarkers, device usage, and healthcare use such as hospitalizations related to heart failure. During the study, participants will undergo evaluations including assessments of their NYHA functional class, six-minute hall walk test, echocardiogram measurements, and blood tests for biomarkers like NT-pro BNP and Troponin HsT. Researchers will monitor hospitalizations over the 12-month follow-up. Each participant will complete the study after 12 months of monitoring following device implantation.

All AgesAll Genders
30 locations
E

Actively Recruiting

This research aims to evaluate the effects of BAROSTIM THERAPY using the BAROSTIM NEO System in people recently implanted with this device for resistant hypertension. The study observes patients implanted under the CE-Marked indication to assess how the therapy works in a commercial setting. The registry includes participants implanted within the past 30 days who meet specific blood pressure and medication resistance criteria. Participants in this registry have the BAROSTIM NEO System implanted and are followed over time without additional treatment interventions, as this is an observational study. Data are collected from standard medical care measurements taken before implantation, at enrollment, and at 3, 6, and 12 months after implantation. After the first year, data collection continues every six months for up to three years, providing long-term observation of therapy impact. During the study, participants undergo regular assessments of blood pressure, changes in cardiovascular medications, and health care use from before implant through three years post-implant. Researchers collect this information during routine care visits, and participants remain under usual medical supervision. The total participation duration can be up to three years from implantation, with data collected at scheduled intervals to monitor the therapys ongoing effects.

All AgesAll Genders
26 locations
C

Actively Recruiting

Researchers are evaluating the use of a new device called the pressure microcatheter to measure the severity of coronary artery lesions in patients with stable coronary artery disease or stabilized non-ST elevation acute coronary syndrome ACS. This trial compares clinical outcomes of patients guided by the pressure microcatheter versus those guided by the conventional pressure wire during percutaneous coronary intervention PCI. The study aims to determine if the pressure microcatheter strategy is not worse than the pressure wire strategy for clinical decision making. Participants will be randomly assigned to receive PCI guided by either the pressure microcatheter or the pressure wire. After an angiographically successful PCI, patients will either undergo fractional flow reserve FFR-guided stent optimization using the assigned device or receive standard care treatment. The interventions are compared in four groups pressure microcatheter with optimization, pressure wire with optimization, pressure microcatheter with standard care, and pressure wire with standard care. Participants will be followed in hospital initially, then at 12 months, and yearly up to five years to monitor clinical outcomes. The study involves collecting data on major adverse cardiac events MACE, procedural times, resource use during hospitalization, post-PCI FFR measurements, and rates of symptoms and complications. This follow-up aims to assess safety, effectiveness, and long-term results of the two guidance strategies.

Age: 18Years - 85YearsAll GendersPhase 4
29 locations
E

Actively Recruiting

Researchers are evaluating the Prevail Drug-Coated Balloon DCB in people with coronary artery disease undergoing percutaneous coronary intervention PCI. The study includes two groups one with in-stent restenosis ISR randomized to receive either the Prevail DCB or the Agent DCB, and another with de novo lesions in small vessel disease DNSV treated with the Prevail DCB and compared to historical data from drug-eluting stents. The study aims to assess the clinical safety and effectiveness of the Prevail DCB in these conditions. Participants in the ISR group will be randomly assigned to receive either the Prevail DCB or the Agent DCB during PCI to treat lesions in coronary arteries previously treated with drug-eluting or bare metal stents. The DNSV group will receive the Prevail DCB for new lesions in small vessels. Both devices are paclitaxel-coated balloons designed for vessels 2.00 mm to 4.00 mm in diameter. Enrollment will take place at about 85 global sites over approximately 12 months. Participants will be followed with clinical assessments for up to 5 years or until study exit or death. Researchers will monitor outcomes such as restenosis, cardiac events including myocardial infarction and death, and the need for repeat procedures at various timepoints from hospital discharge through 5 years. Safety and efficacy will be tracked through visits and evaluations at 30 days, 6, 12, 24, 36, 48, and 60 months after the procedure to gather long-term data on the devices.

Age: 18Years +All GendersPhase Not Applicable
79 locations
C

Actively Recruiting

Coronary artery disease occurs when the arteries narrow, sometimes requiring a procedure called Percutaneous Coronary Intervention PCI to open them. This study focuses on treating calcified coronary artery lesions, which can make stent placement difficult. Researchers are comparing two devices that use sonic pressure waves to break up calcified plaques the newer ShockFast IVL and the more established Shockwave IVL. The trial aims to assess how these devices perform in treating these challenging lesions. Participants receive treatment with one of two devices during PCI. The ShockFast IVL device uses sonic pressure waves to safely fracture calcium deposits, aiming to keep the artery flexible and allow smoother stent placement. It offers an improved crossing profile and two catheter lengths. The Shockwave IVL device also uses sonic pressure waves but has only one catheter length. Both devices are used during the coronary intervention procedure to modify calcified plaques. During the study, participants undergo PCI with one of the two devices. Researchers measure the stent area at the narrowest artery point during the procedure using optical coherence tomography OCT. Additional outcomes include target lesion failure, angiographic success, and device success assessed up to 30 days after the procedure. The study involves hospital assessments during the procedure and follow-up visits over 30 days to monitor safety and effectiveness. The trial is expected to complete by March 2027.

Age: 18Years +All GendersPhase Not Applicable
13 locations